This 2-day training offered by psychologists Ingmar Gorman and Elizabeth Nielson is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. This interactive training includes experiential learning and role-play exercises. It is the first time a program of this kind has been offered in Montreal.

Psychedelics 101: Your patients are curious and so are you: What is all this about psychedelics being used for treatment of addiction and trauma? This session gives an overview of psychedelic drugs, their history, and current research with MDMA and Psilocybin-assisted therapy. This program includes overview of recent and current clinical trials, outcomes, legal status, and what it all means for the future of addiction and trauma treatment.

Learning Objectives:

  • State the historical justifications for psychedelic clinical research
  • Describe key theoretical approaches to psychedelic-assisted therapy
  • Discuss the state of psychedelic clinical research, rescheduling efforts, and how psychedelic-assisted psychotherapy works with clients.
  • Define and differentiate psychedelic integration psychotherapy from integration in peer and shamanic settings

Psychedelics 102: What are psychedelic harm reduction and integration and how can they occur in a clinical setting? This session focuses on translating research findings into clinical practice including working with patients who are considering using psychedelics, actually using psychedelics, or have used them. This program includes discussion of assessment and integration techniques, resources, and legal and ethical issues.

Learning Objectives:

  • Identify key “red flags” that indicate someone should seek specialized psychiatric care after a psychedelic experience
  • Perform basic/initial assessment of clients who report psychedelic use
  • Identify contraindications and discuss high risk cases of individuals who are contemplating psychedelic use
  • Define and differentiate the role of the therapist in an individual’s psychotherapeutic process

Fees:

Full program cost: $525

Limited number of early registration tickets available until July 1st for $475. Early-bird pricing extended until July 8th.

Limited number of student registration tickets available for $395

$50 USD for APA CE credits

CONTINUING EDUCATION INFORMATION

OPQ credits approval process in underway and will be posted here when confirmed.

CE credits for psychologists are provided by the Spiritual Competency Resource Center (SCRC) which is co-sponsoring this program. The Spiritual Competency Resource Center is approved by the American Psychological Association to sponsor continuing education for psychologists. The Spiritual Competency Resource Center maintains responsibility for this program and its content. SCRC is approved by the California Board of Registered Nursing (BRN Provider CEP16887) for licensed nurses in California. The California Board of Behavioral Sciences accepts CE credits for LCSW, LPCC, LEP, and LMFT license renewal for programs offered by approved sponsors of CE by the American Psychological Association.

For questions about receiving your Certificate of Attendance, contact Woodstock Mindfulness at CE@marverde.info

Instructors


Ingmar Gorman, Ph.D.

Ingmar Gorman, Ph.D., is a psychologist who specializes in assisting populations who have had experiences with psychedelics and other psychoactive compounds. He is the Director of the Psychedelic Education and Continuing Care Program, where he leads groups, trainings, and works with individual clients. Dr. Gorman is also site co-principal Investigator and therapist on a Phase 3 clinical trial studying the potential psychotherapeutic utility of MDMA for post-traumatic stress disorder. He is a NIH funded fellow at New York University and a board member of Horizons Media, Inc., a not for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics.

Elizabeth Nielson, Ph.D.

Dr. Elizabeth Nielson is a psychologist with a holistic, compassionate, and integrative approach to psychotherapy. She specializes in treating addictive and mood disorders with a blend of of mindfulness-based interventions, dialectical behavior therapy, psychodynamic therapy, community reinforcement and family training (CRAFT), and principles of psychedelic-assisted therapy. Dr. Nielson is part of the Experimental Therapeutics Research Laboratory at NYU Langone School of Medicine where she is a therapist on the psilocybin-assisted treatment for alcohol dependence trial and on the MDMA-assisted psychotherapy for PTSD clinical trials.